148
Participants
Start Date
March 13, 2023
Primary Completion Date
March 1, 2025
Study Completion Date
March 1, 2026
SNP-ACTH (1-39) Gel
Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
Rituximab
Subjects will be randomly assigned in 1:1 treatment allocation ratio to receive the test and reference product.
RECRUITING
NYU Langone Health, New York
RECRUITING
Sir Ganga Ram Hospital, New Delhi
RECRUITING
Nephrology Associates of Northern Virginia, Fairfax
RECRUITING
University of Virginia, Charlottesville
RECRUITING
Fides Clinical Research, Atlanta
RECRUITING
Costal Medical Research, Brunswick
RECRUITING
South Florida Nephrology Research, Coral Springs
RECRUITING
Reliant Medical Research, LLC, Miami
RECRUITING
Vista Health Research, LLC, Miami
RECRUITING
Therafirst Medical Center, Fort Lauderdale
RECRUITING
RecioMed Clinical Research Network, Inc., Boynton Beach
RECRUITING
Genesis Clinical Research, Tampa
RECRUITING
Center for Advanced Kidney Research, PLC, Saint Clair Shores
RECRUITING
University of Iowa, Iowa City
RECRUITING
Insight Hospital and Medical Center Chicago, Chicago
RECRUITING
P&I Clinical Research LLC, Lufkin
RECRUITING
Prolato Clinical Research Center, Houston
RECRUITING
Academic Medical Research Institute, Los Angeles
RECRUITING
Valiance Clinical Research, Tarzana
RECRUITING
North America Research Institute, San Dimas
RECRUITING
PGIMER, Chandigarh
RECRUITING
Galaxy Hospital, Varanasi
RECRUITING
SMS Medical College and Hospital, Jaipur
RECRUITING
Apex Hospitals, Jaipur
RECRUITING
Saraswati Kidney Care Center, Nagpur
RECRUITING
AIIMS, Raipur
RECRUITING
Vedanta Hospitals, Guntur
RECRUITING
Vijaya Super Speciality Hospital, Nellore
RECRUITING
KLE Hospital, Belagavi
RECRUITING
Regional Kidney Wellness Centre, Brampton
RECRUITING
Muljibhai Patel Urological Hospital, Nadiād
Lead Sponsor
Cerium Pharmaceuticals, Inc.
INDUSTRY